Codexis (CDXS) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Codexis (CDXS) overview

Codexis (CDXS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 70.4m and operating profit of USD -41.7m; the year-end share price was 1.63 USD and market capitalisation was USD 147m. Codexis is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Codexis's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 50.5mFY 2025
Share price1.63 USDFY 2025 year end
RevenueUSD 70.4mFY 2025
Operating profitUSD -41.7mFY 2025
Net earningsUSD -44.0mFY 2025
Market capitalisationUSD 147mFY 2025 year end

About Codexis

Codexis provides technology solutions for improving therapeutics manufacturing, using its CodeEvolver directed evolution platform to develop and commercialize enzymes and other proteins. Its ECO Synthesis platform offers enzymatic tools and processes for manufacturing RNA interference therapeutics, alongside process and analytical development services. The company also develops enzymes for pharmaceutical manufacturers to improve the production processes of small molecule therapeutics, including through higher yields and purity.

Generate the Codexis report

Codexis is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Codexis and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Codexis

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.